This Week’s Top Stories in Biotech
Most Popular - Jason Napodano laid out the DRRX investment thesis. Will Pfizer re-file the Remoxy NDA? And what about Posidur? They’re both real value drivers for DRRX, … Continue Reading
Read NowRecap
PropThink’s Lead Stories in Biotech
Long Ideas - On Friday, PropThink launched its database of Special Protocol Assessments, or SPAs. These trials are, in essence, a FDA-blessed measure to mitigate clinical efficacy risk … Continue Reading
Read NowThe PropThink Weekly Recap
Long Ideas - PropThink’s first story of the week turned into a whopping 24% gainer by Friday’s close. We iterated our enthusiasm for Pharmacyclics (PCYC) on Monday, following … Continue Reading
Read NowPropThink’s Weekly Healthcare Wrap-Up
Most Popular - IMUC proved a successful trade in the short-term, climbing 34% since our report was published on the first of the month. In early trials, lead … Continue Reading
Read NowPropThink’s Weekly Roundup
Most Popular - The event of the week? Phase III data for Zerenex, Keryx Biopharmaceutical’s phosphate binder, were released on Monday, with compelling results. PropThink has been covering … Continue Reading
Read NowPropThink’s Healthcare Week-in-Review
Long Ideas - The highlight of our week was Allergan’s ~$1B buyout of MAP Pharmaceuticals, a company that we recommended in early January. The acquisition came at a … Continue Reading
Read NowThe PropThink Weekly Wrap-Up
Most Popular - The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and … Continue Reading
Read Now